Arrowhead Pharmaceuticals Tech Stack
Clinical-stage RNAi biotech advancing siRNA therapeutics from discovery to regulatory approval
Arrowhead Pharmaceuticals is a public biotech firm developing RNA interference (RNAi) therapeutics, with 501–1,000 employees split between discovery, manufacturing, and clinical operations. The hiring footprint reveals a manufacturing-heavy operation: 31 of 154 active roles target manufacturing roles, with significant concurrent staffing in research and quality—a profile consistent with ramping GMP production and regulatory submissions for clinical candidates. Pain-point concentration on compliance, inspection readiness, and vendor management signals active engagement with FDA oversight and supply-chain hardening ahead of or during regulatory reviews.
Tech Stack 34 technologies
What Arrowhead Pharmaceuticals Is Building
◆Challenges
- Ensuring compliance with gmp regulations
- Inspection readiness
- Ensuring durable access and pull-through
- Audit readiness for regulatory inspections
- Quality event management
- Maintaining compliance with healthcare regulations
- Ensuring data privacy compliance
- Compliance with global gxp regulations
- Vendor compliance management
- Quality compliance challenges
▲Active Projects
- Risk management and control plan development
- Sop lifecycle management
- Digital workflow implementation
- Antibody development and screening
- Raw materials supplier qualification
- Plozasiran evidence generation
- Regulatory submissions
- Clinical pathway integration
- Regulatory inspection coordination
- Identifying and optimizing novel peptide ligands for sirna delivery
Hiring Activity
Department
Seniority
Notable leadership hires: Medical Director, Key Account Associate Director, Director, Key Account, Field Medical Lead
